Investing

Repligen : RGEN

RGEN

Stock Data

$117.20

$1.11 (0.94%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

MEDICAL INSTRUMENTS & SUPPLIES

Repligen Corporation is a pioneer in bioprocessing technologies, playing a crucial role in the manufacturing of biological drugs globally. With a product lineup that includes Protein A ligands essential for drug purification, innovative chromatography columns like OPUS, and a range of filtration devices, Repligen supports the biopharmaceutical industry's need for high-quality drug production. Their offerings extend to ELISA test kits and process analytics products, catering to life sciences, diagnostics, and biopharmaceutical companies. Founded in 1981 and based in Waltham, Massachusetts, Repligen is committed to advancing biomanufacturing with its collaborative and innovative solutions.

All Repligen Articles

4 Articles

Lee Jackson | Mar 29, 2023 at 8:52 AM EDT

Wednesday’s Top Analyst Upgrades and Downgrades: Carnival, Fox, Marathon Petroleum, Occidental Petroleum, Paramount, Salesforce and More

Wednesday's top analyst upgrades and downgrades included Array Technology, Blink Charging, Carnival, Carrier Global, DocuSign, Fox, Marathon Petroleum, Occidental Petroleum,…

Lee Jackson | Dec 15, 2022 at 8:38 AM EST

Thursday’s Top Analyst Upgrades and Downgrades: Amgen, ADM, Blackstone, Bloom Energy, Carnival, Chevron, Nike, QuantumScape, RingCentral and More

Thursday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Blackstone, Bloom Energy, Carnival, Chevron, Danaher, EQT, KKR, Nike,…

Lee Jackson | Oct 4, 2022 at 8:52 AM EDT

Tuesday’s Top Analyst Upgrades and Downgrades: Ally Financial, CarMax, Dynatrace, Exelon, Gilead Sciences, KKR, Lowe’s, Morgan Stanley, Tesla and More

Tuesday's top analyst upgrades and downgrades included Ally Financial, CarMax, Dominion Energy, Dynatrace, Exelon, GigaCloud Technology, Gilead Sciences, Intuit, KKR,…

Chris Lange | Jan 21, 2020 at 10:00 AM EST

Winning Ideas in Biotech/Pharma After JPMorgan Healthcare Conference

For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past…